NO20020662L - Pyrimidin-2,4,6-trion metalloproteinase inhibitorer - Google Patents

Pyrimidin-2,4,6-trion metalloproteinase inhibitorer

Info

Publication number: NO20020662L
Authority: NO; Norway
Prior art keywords: pyrimidine; metalloproteinase inhibitors; trione metalloproteinase; trione; inhibitors
Prior art date: 1999-08-12

Application number

NO20020662A

Other languages

English (en)

Norwegian (no)

Other versions

NO20020662D0 (no

Inventor

Julian Blagg

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-12

Filing date

2002-02-11

Publication date

2002-04-09

2002-02-11 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2002-02-11 Publication of NO20020662D0 publication Critical patent/NO20020662D0/no

2002-04-09 Publication of NO20020662L publication Critical patent/NO20020662L/no

Links

HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 title 1
239000003475 metalloproteinase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20020662A 1999-08-12 2002-02-11 Pyrimidin-2,4,6-trion metalloproteinase inhibitorer NO20020662L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US14854799P	1999-08-12	1999-08-12
PCT/IB2000/001090 WO2001012611A1 (fr)	1999-08-12	2000-08-03	Inhibiteurs de pyrimidine-2,4,6-trione metalloproteinase

Publications (2)

Publication Number	Publication Date
NO20020662D0 NO20020662D0 (no)	2002-02-11
NO20020662L true NO20020662L (no)	2002-04-09

Family

ID=22526231

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20020662A NO20020662L (no)	1999-08-12	2002-02-11	Pyrimidin-2,4,6-trion metalloproteinase inhibitorer

Country Status (41)

Country	Link
US (1)	US6579982B1 (fr)
EP (1)	EP1202974B1 (fr)
JP (1)	JP2003507371A (fr)
KR (2)	KR20040073608A (fr)
CN (1)	CN1156454C (fr)
AR (1)	AR025091A1 (fr)
AT (1)	ATE309224T1 (fr)
AU (1)	AU773751B2 (fr)
BG (1)	BG106406A (fr)
BR (1)	BR0013081A (fr)
CA (1)	CA2381551A1 (fr)
CO (1)	CO5180629A1 (fr)
CR (1)	CR6565A (fr)
CZ (1)	CZ2002355A3 (fr)
DE (1)	DE60023903D1 (fr)
EA (1)	EA004680B1 (fr)
EC (1)	ECSP003610A (fr)
EE (1)	EE200200069A (fr)
GE (1)	GEP20053424B (fr)
GT (1)	GT200000137A (fr)
HK (1)	HK1045995B (fr)
HN (1)	HN2000000137A (fr)
HR (1)	HRP20020129A2 (fr)
HU (1)	HUP0202501A3 (fr)
IL (1)	IL148035A0 (fr)
IS (1)	IS6248A (fr)
MA (1)	MA26812A1 (fr)
MX (1)	MXPA02001561A (fr)
NO (1)	NO20020662L (fr)
NZ (1)	NZ516562A (fr)
OA (1)	OA12000A (fr)
PA (1)	PA8498701A1 (fr)
PE (1)	PE20010491A1 (fr)
PL (1)	PL353871A1 (fr)
SK (1)	SK1652002A3 (fr)
TN (1)	TNSN00169A1 (fr)
TR (1)	TR200200381T2 (fr)
UY (1)	UY26285A1 (fr)
WO (1)	WO2001012611A1 (fr)
YU (1)	YU6602A (fr)
ZA (1)	ZA200201070B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en)	1998-12-23	2005-02-22	G. D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EE200300195A (et) *	2000-10-26	2003-10-15	Pfizer Products Inc.	Pürimidiin-2,4,6-trioonmetalloproteinaasi inhibiitorid
US6841671B2 (en)	2000-10-26	2005-01-11	Pfizer Inc.	Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
EP1332146A2 (fr) *	2000-10-26	2003-08-06	Pfizer Products Inc.	Inhibiteurs de metalloproteinase spiro-pyrimidine-2,4,6-trione
WO2002064571A1 (fr)	2001-02-14	2002-08-22	Warner-Lambert Company Llc	Pyrimidine comme inhibiteurs de la métalloprotéinase de matrice
DOP2002000333A (es)	2001-02-14	2002-09-30	Warner Lambert Co	Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
ATE280164T1 (de)	2001-02-14	2004-11-15	Warner Lambert Co	Benzothiadiazine als matrix metallproteinase inhibitoren
DOP2002000332A (es)	2001-02-14	2002-08-30	Warner Lambert Co	Inhibidores de piridina de metaloproteinasas de la matriz
PA8539501A1 (es)	2001-02-14	2002-09-30	Warner Lambert Co	Compuestos triazolo como inhibidores de mmp
US6924276B2 (en)	2001-09-10	2005-08-02	Warner-Lambert Company	Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
JP2003081838A (ja) *	2001-09-11	2003-03-19	Rohto Pharmaceut Co Ltd	グルコサミン製剤
EP1434585A1 (fr)	2001-10-12	2004-07-07	Warner-Lambert Company LLC	Inhibiteurs de metalloproteinase matricielle (mmp) a base d'alkyne
US6962922B2 (en)	2001-10-12	2005-11-08	Warner-Lambert Company Llc	Alkynylated quinazoline compounds
AU2002346729A1 (en)	2001-12-20	2003-07-09	Bristol-Myers Squibb Company	Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
US6894057B2 (en)	2002-03-08	2005-05-17	Warner-Lambert Company	Oxo-azabicyclic compounds
AU2003220401A1 (en)	2002-03-18	2003-10-08	Bristol-Myers Squibb Company	Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
NI200300045A (es)	2002-04-26	2005-07-08	Pfizer Prod Inc	Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
DE60302150D1 (en) *	2002-04-26	2005-12-08	Pfizer Prod Inc	N-substituiete heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trion metalloproteinase inhibitoren
JP2005529889A (ja) *	2002-04-26	2005-10-06	ファイザー・プロダクツ・インク	ピリミジン−２，４，６−トリオンメタロ−プロテイナーゼ阻害剤
ES2247527T3 (es) *	2002-04-26	2006-03-01	Pfizer Prod Inc	Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona.
AU2003250471A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
WO2004014866A1 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Derives d'azaisoquinoline utilises comme inhibiteurs de metalloproteases matricielles
EP1537098A1 (fr)	2002-08-13	2005-06-08	Warner-Lambert Company LLC	Derives monocycliques en tant qu'inhibiteurs de metalloproteinases matricielles
AU2003250470A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Pyrimidinone fused bicyclic metalloproteinase inhibitors
AU2003250466A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
BR0313384A (pt)	2002-08-13	2005-07-12	Warner Lambert Co	Derivados de cromona como inibidores de metaloproteinases de matriz
PA8578101A1 (es)	2002-08-13	2004-05-07	Warner Lambert Co	Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
AU2003249477A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Heterobicylcic metalloproteinase inhibitors
WO2004014909A1 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Derives fusionnes de la tetrahydropyridine inhibiteurs de la metalloprotease matricielle
AU2003249540A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Fused bicyclic metalloproteinase inhibitors
WO2004084903A1 (fr) *	2003-03-27	2004-10-07	F. Hoffmann-La Roche Ag	Utilisation d'une trioxopyrimidine pour le traitement et la prevention de l'angiogenese pathologique oculaire
WO2004084902A1 (fr) *	2003-03-28	2004-10-07	F. Hoffmann-La Roche Ag	Utilisation d'une trioxopyrimidine dans le traitement de lesions chroniques
EP1613269B1 (fr)	2003-04-04	2015-02-25	Incyte Corporation	Compositions, procedes et kits relatifs au clivage de her-2
US20050107350A1 (en) *	2003-08-22	2005-05-19	Pharmacia Corporation	Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
WO2012014109A1 (fr)	2010-07-30	2012-02-02	Ranbaxy Laboratories Limited	Sulfamides hétérocycliques servant d'inhibiteurs de synthétase d'arn de transfert, destinés à être utilisés en tant qu'agents antibactériens
TW201512171A (zh)	2013-04-19	2015-04-01	Pfizer Ltd	化學化合物
US20150366275A1 (en) *	2014-06-19	2015-12-24	Gyula Cserfoi	Wearable Signaling Device
GB201705255D0 (en)	2017-03-31	2017-05-17	Univ I Tromsø - Norges Arktiske Univ	Bioactive cyclic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ62799A3 (cs) *	1996-08-28	1999-07-14	The Procter & Gamble Company	Heterocyklické metaloproteázové inhibitory
ES2247707T3 (es) *	1997-06-21	2006-03-01	Roche Diagnostics Gmbh	Derivados del acido barbiturico con actividad antimetastasica y antitumoral.

2000
- 2000-07-20 PA PA20008498701A patent/PA8498701A1/es unknown
- 2000-07-20 HN HN2000000137A patent/HN2000000137A/es unknown
- 2000-08-03 EP EP00946235A patent/EP1202974B1/fr not_active Expired - Lifetime
- 2000-08-03 HR HR20020129A patent/HRP20020129A2/xx not_active Application Discontinuation
- 2000-08-03 CA CA002381551A patent/CA2381551A1/fr not_active Abandoned
- 2000-08-03 DE DE60023903T patent/DE60023903D1/de not_active Expired - Lifetime
- 2000-08-03 SK SK165-2002A patent/SK1652002A3/sk unknown
- 2000-08-03 CZ CZ2002355A patent/CZ2002355A3/cs unknown
- 2000-08-03 HK HK02107534.6A patent/HK1045995B/zh not_active IP Right Cessation
- 2000-08-03 BR BR0013081-8A patent/BR0013081A/pt not_active IP Right Cessation
- 2000-08-03 AU AU60105/00A patent/AU773751B2/en not_active Ceased
- 2000-08-03 KR KR10-2004-7011899A patent/KR20040073608A/ko not_active Ceased
- 2000-08-03 JP JP2001517509A patent/JP2003507371A/ja active Pending
- 2000-08-03 YU YU6602A patent/YU6602A/sh unknown
- 2000-08-03 PL PL00353871A patent/PL353871A1/xx not_active Application Discontinuation
- 2000-08-03 WO PCT/IB2000/001090 patent/WO2001012611A1/fr not_active Ceased
- 2000-08-03 EE EEP200200069A patent/EE200200069A/xx unknown
- 2000-08-03 OA OA1200200030A patent/OA12000A/en unknown
- 2000-08-03 CN CNB008113920A patent/CN1156454C/zh not_active Expired - Fee Related
- 2000-08-03 TR TR2002/00381T patent/TR200200381T2/xx unknown
- 2000-08-03 NZ NZ516562A patent/NZ516562A/xx unknown
- 2000-08-03 AT AT00946235T patent/ATE309224T1/de not_active IP Right Cessation
- 2000-08-03 IL IL14803500A patent/IL148035A0/xx unknown
- 2000-08-03 KR KR1020027001880A patent/KR20020047119A/ko not_active Abandoned
- 2000-08-03 EA EA200200058A patent/EA004680B1/ru not_active IP Right Cessation
- 2000-08-03 HU HU0202501A patent/HUP0202501A3/hu unknown
- 2000-08-03 MX MXPA02001561A patent/MXPA02001561A/es active IP Right Grant
- 2000-08-03 GE GE4688A patent/GEP20053424B/en unknown
- 2000-08-04 CO CO00058849A patent/CO5180629A1/es not_active Application Discontinuation
- 2000-08-09 EC EC2000003610A patent/ECSP003610A/es unknown
- 2000-08-09 UY UY26285A patent/UY26285A1/es not_active Application Discontinuation
- 2000-08-09 US US09/635,156 patent/US6579982B1/en not_active Expired - Fee Related
- 2000-08-10 PE PE2000000811A patent/PE20010491A1/es not_active Application Discontinuation
- 2000-08-10 GT GT200000137A patent/GT200000137A/es unknown
- 2000-08-10 AR ARP000104130A patent/AR025091A1/es unknown
- 2000-08-11 TN TNTNSN00169A patent/TNSN00169A1/fr unknown
2002
- 2002-01-25 IS IS6248A patent/IS6248A/is unknown
- 2002-01-29 CR CR6565A patent/CR6565A/es not_active Application Discontinuation
- 2002-02-07 MA MA26512A patent/MA26812A1/fr unknown
- 2002-02-07 ZA ZA200201070A patent/ZA200201070B/en unknown
- 2002-02-11 NO NO20020662A patent/NO20020662L/no not_active Application Discontinuation
- 2002-02-12 BG BG06406A patent/BG106406A/xx unknown

Also Published As

Publication number	Publication date
CR6565A (es)	2004-02-23
GEP20053424B (en)	2005-01-25
HN2000000137A (es)	2001-02-02
SK1652002A3 (en)	2002-09-10
HK1045995B (zh)	2004-12-31
YU6602A (sh)	2004-11-25
OA12000A (en)	2006-04-18
IL148035A0 (en)	2002-09-12
EP1202974B1 (fr)	2005-11-09
AR025091A1 (es)	2002-11-06
JP2003507371A (ja)	2003-02-25
EP1202974A1 (fr)	2002-05-08
UY26285A1 (es)	2001-03-16
HUP0202501A3 (en)	2003-02-28
CA2381551A1 (fr)	2001-02-22
KR20040073608A (ko)	2004-08-19
TR200200381T2 (tr)	2002-05-21
ATE309224T1 (de)	2005-11-15
PE20010491A1 (es)	2001-04-25
ECSP003610A (es)	2002-03-25
ZA200201070B (en)	2003-04-30
EA004680B1 (ru)	2004-06-24
WO2001012611A1 (fr)	2001-02-22
BG106406A (en)	2002-09-30
HRP20020129A2 (en)	2004-04-30
HUP0202501A2 (hu)	2002-12-28
GT200000137A (es)	2002-02-01
BR0013081A (pt)	2002-04-23
NO20020662D0 (no)	2002-02-11
US6579982B1 (en)	2003-06-17
DE60023903D1 (de)	2005-12-15
CN1156454C (zh)	2004-07-07
CZ2002355A3 (cs)	2002-07-17
PL353871A1 (en)	2003-12-01
MXPA02001561A (es)	2002-07-02
AU6010500A (en)	2001-03-13
HK1045995A1 (en)	2002-12-20
CN1368963A (zh)	2002-09-11
CO5180629A1 (es)	2002-07-30
AU773751B2 (en)	2004-06-03
TNSN00169A1 (fr)	2005-11-10
EE200200069A (et)	2003-04-15
KR20020047119A (ko)	2002-06-21
EA200200058A1 (ru)	2002-06-27
IS6248A (is)	2002-01-25
PA8498701A1 (es)	2002-08-26
NZ516562A (en)	2003-06-30
MA26812A1 (fr)	2004-12-20

Legal Events

Date	Code	Title	Description
2006-03-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20020662L (no)	2002-04-09	Pyrimidin-2,4,6-trion metalloproteinase inhibitorer
NO20031852L (no)	2003-06-23	Pyrimidin-2,4,6-trion metalloproteinase inhibitorer
EE200300196A (et)	2003-10-15	Spiropürimidiin-2,4,6-trioonmetalloproteinaasi inhibiitorid
ATE372988T1 (de)	2007-09-15	Pyrimidin-derivate
MA26881A1 (fr)	2004-12-20	5-alkyl-pyrido [2,3-d]pyrimidines inhibitrices de tyrosine-kinases.
ATE455107T1 (de)	2010-01-15	Hiv-replikationshemmende pyrimidine
CY2015035I2 (el)	2016-04-13	Ενωσεις πυριμιδινης
ATE223401T1 (de)	2002-09-15	Dihydropyrimidine
DK1175408T3 (da)	2005-04-11	Pyrimidinonforbindelser
NO20024127D0 (no)	2002-08-29	Pyrimidin-forbindelser
EP1161433A4 (fr)	2002-05-08	Inhibiteurs de tyrosine kinase
ATE256123T1 (de)	2003-12-15	Pyrimidonderivate
NO20021820L (no)	2002-05-23	Tyrosinkinaseinhibitorer
AU2003219410A8 (en)	2003-11-10	Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
ATE277912T1 (de)	2004-10-15	Pyrimidine-2,4,6-trione als matrixmetalloproteinase-hemmer
DE50103649D1 (de)	2004-10-21	2-aminoalkyl-thieno[2,3-d]pyrimidine
ATE286030T1 (de)	2005-01-15	1,4,5,6 -tetrahydropyrimidine-derivative als vitronectin-hemmer